The Clinical Evidence Base for Epigenetic Medicine

Aging Is Medicine's Biggest Blind Spot

ARPA-H's PROSPR program is launching the first Phase 3 clinical trial targeting aging itself — not a single disease — using FDA-approved drugs and a validated biomarker score designed to predict 20-year health outcomes. A $38 trillion opportunity is finally getting the clinical infrastructure it deserves.

ARPA-H's mandate to build validated aging biomarker scores and accessible home testing kits is a direct validation of XELGEN's clinical thesis. Our genome-wide DNA methylation platform already delivers the multi-system biological age intelligence that PROSPR is working to standardise — positioning XELGEN as the epigenetic layer that longevity medicine needs right now, not in 2031.

Epigenetic Patterns, Accelerated Biological Aging & Epigenetic Drift Detected 6 Months Following COVID-19 Infection

A genome-wide DNA methylation study of 96 post-COVID-19 patients found significant epigenetic age acceleration via Horvath's clock, 42 dysregulated CpG sites, and a substantial increase in stochastic epigenetic mutations — pointing to lasting biological damage across immune, vascular, and metabolic pathways, regardless of initial infection severity.

Biological ageing is not solely a function of time — it is actively shaped by conditions like COVID-19, which can accelerate epigenetic clocks and trigger lasting drift across immune, vascular, and metabolic pathways. XELGEN's genome-wide DNA methylation platform provides the most comprehensive and personalised epigenetic screening available, identifying current biological age acceleration and early signals of future risk before they manifest as disease.

The Race to Measure Aging — And Why It Matters

Scientists are racing to develop reliable biological age tests — and the results could reshape how we think about health, disease, and longevity. DNA methylation clocks are emerging as the most validated approach.

This TIME feature validates the clinical demand for epigenetic age measurement. XELGEN's genome-wide DNA methylation platform — built on Illumina EPIC arrays — delivers exactly the validated, physician-grade biological age insights the field is calling for.

With FDA Go-Ahead, a China Biotech Notches a First in Cell Therapy Testing

The FDA has cleared Shanghai-based Unixell to begin human studies of an allogeneic, stem cell-derived therapy targeting focal epilepsy — marking a new frontier for cell therapy indications globally.

Stem cell therapies for diverse disease indications are set to explode. What the field critically needs is XELGEN's Cell Intelligence platform to ensure cellular changes are continuously monitored, validated, and clinically documented throughout treatment.

FDA Greenlights Life Biosciences' Gene Therapy Study to Rewind the Age of Cells

In a major test for the longevity field, the FDA has cleared Life Biosciences to study a gene therapy designed to achieve a 'near total reset' of cellular age — co-founded by Harvard's David Sinclair.

Advancements in cell and gene therapy are pushing the boundaries of what's biologically possible. Yet there is a critical gap: the lack of standardized monitoring systems. XELGEN's Cell Intelligence platform provides exactly the epigenetic tracking infrastructure needed to document and validate these cellular age changes in real time.

3 New Venture Funds Collect Nearly $1B for Biotech in US & EU

A16z, BioNTech/Penn, and Servier Ventures have collectively raised nearly $1 billion in new biotech-focused funds, signaling strong investor conviction in next-generation life sciences platforms.

The surge in biotech venture capital reflects growing investor confidence in precision medicine platforms. XELGEN is positioned at the intersection of epigenomics, regenerative medicine, and clinical diagnostics — exactly the convergence point that top-tier funds are actively seeking to back.

NY Giants Team Doctor: Clinics Offering 'Miracle Injections' Are Selling False Hope

The head team physician for the New York Giants warns that regenerative medicine marketing has outpaced the science — and that unregulated stem cell clinics are putting patients at serious risk.

This is precisely why objective, validated cell therapy screening is essential. XELGEN's Cell Intelligence platform provides the epigenetic monitoring infrastructure that ensures regenerative therapies are not only administered — but rigorously tracked, validated, and proven effective for each individual patient.